231,380 Shares in Xenon Pharmaceuticals Inc. $XENE Acquired by Eversept Partners LP

Eversept Partners LP bought a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) in the 4th quarter, HoldingsChannel.com reports. The fund bought 231,380 shares of the biopharmaceutical company’s stock, valued at approximately $10,370,000.

Several other hedge funds and other institutional investors have also bought and sold shares of XENE. Goldman Sachs Group Inc. boosted its stake in Xenon Pharmaceuticals by 7.9% in the first quarter. Goldman Sachs Group Inc. now owns 442,732 shares of the biopharmaceutical company’s stock worth $14,854,000 after buying an additional 32,486 shares in the last quarter. Jump Financial LLC purchased a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at approximately $532,000. Sei Investments Co. purchased a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at approximately $711,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Xenon Pharmaceuticals during the second quarter valued at approximately $816,000. Finally, Alliancebernstein L.P. boosted its stake in shares of Xenon Pharmaceuticals by 14.2% during the second quarter. Alliancebernstein L.P. now owns 1,518,527 shares of the biopharmaceutical company’s stock valued at $47,530,000 after purchasing an additional 189,141 shares during the period. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Xenon Pharmaceuticals Stock Up 2.3%

Shares of XENE stock opened at $53.20 on Thursday. The stock has a fifty day moving average of $55.16 and a 200 day moving average of $49.17. Xenon Pharmaceuticals Inc. has a 52 week low of $30.00 and a 52 week high of $63.95. The firm has a market capitalization of $5.14 billion, a price-to-earnings ratio of -11.32 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, hitting analysts’ consensus estimates of ($1.17). During the same period in the previous year, the business posted ($0.83) earnings per share. Equities research analysts anticipate that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current year.

Analysts Set New Price Targets

XENE has been the subject of a number of analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Xenon Pharmaceuticals in a research note on Wednesday, April 8th. JPMorgan Chase & Co. increased their price objective on Xenon Pharmaceuticals from $80.00 to $82.00 and gave the company an “overweight” rating in a research note on Wednesday, May 27th. Wedbush dropped their price objective on Xenon Pharmaceuticals from $64.00 to $63.00 and set an “outperform” rating for the company in a research note on Monday, March 16th. Jefferies Financial Group set a $100.00 price objective on Xenon Pharmaceuticals in a research note on Monday, March 9th. Finally, Morgan Stanley set a $97.00 price objective on Xenon Pharmaceuticals in a research note on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $77.20.

Insiders Place Their Bets

In related news, Director Gary Patou sold 1,322 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the sale, the director owned 24,896 shares of the company’s stock, valued at $1,322,973.44. This trade represents a 5.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Gillian Cannon sold 1,190 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $53.14, for a total value of $63,236.60. Following the completion of the sale, the director directly owned 1,455 shares of the company’s stock, valued at $77,318.70. The trade was a 44.99% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 4.07% of the company’s stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical?stage biopharmaceutical company dedicated to discovering and developing novel, small?molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion?channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion?channel biology and structure?based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.